JP2010525826A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525826A5 JP2010525826A5 JP2010506716A JP2010506716A JP2010525826A5 JP 2010525826 A5 JP2010525826 A5 JP 2010525826A5 JP 2010506716 A JP2010506716 A JP 2010506716A JP 2010506716 A JP2010506716 A JP 2010506716A JP 2010525826 A5 JP2010525826 A5 JP 2010525826A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- strand
- nucleotide
- nucleotide sequence
- guide strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 84
- 239000002773 nucleotide Substances 0.000 claims 78
- 108020004707 nucleic acids Proteins 0.000 claims 24
- 150000007523 nucleic acids Chemical class 0.000 claims 24
- 102000039446 nucleic acids Human genes 0.000 claims 24
- 108700011259 MicroRNAs Proteins 0.000 claims 16
- 239000002679 microRNA Substances 0.000 claims 16
- 230000003278 mimic effect Effects 0.000 claims 11
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 8
- 230000000295 complement effect Effects 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 5
- -1 Aminopropyl Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108091029119 miR-34a stem-loop Proteins 0.000 claims 3
- 108091079013 miR-34b Proteins 0.000 claims 3
- 108091084018 miR-34b stem-loop Proteins 0.000 claims 3
- 108091063470 miR-34b-1 stem-loop Proteins 0.000 claims 3
- 108091049916 miR-34b-2 stem-loop Proteins 0.000 claims 3
- 108091057222 miR-34b-3 stem-loop Proteins 0.000 claims 3
- 108091092639 miR-34b-4 stem-loop Proteins 0.000 claims 3
- 108091090583 miR-34c stem-loop Proteins 0.000 claims 3
- 108091082133 miR-34c-1 stem-loop Proteins 0.000 claims 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 229940124447 delivery agent Drugs 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 230000001293 nucleolytic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 244000089409 Erythrina poeppigiana Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 claims 1
- 238000000137 annealing Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92762107P | 2007-05-03 | 2007-05-03 | |
| PCT/US2008/062689 WO2008137867A2 (en) | 2007-05-03 | 2008-05-05 | Compositions comprising mir34 therapeutic agents for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010525826A JP2010525826A (ja) | 2010-07-29 |
| JP2010525826A5 true JP2010525826A5 (OSRAM) | 2011-06-23 |
Family
ID=39944228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506716A Pending JP2010525826A (ja) | 2007-05-03 | 2008-05-05 | 癌を治療するためのｍｉｒ３４治療剤を含む組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8399248B2 (OSRAM) |
| EP (1) | EP2152722B1 (OSRAM) |
| JP (1) | JP2010525826A (OSRAM) |
| AU (1) | AU2008247427A1 (OSRAM) |
| CA (1) | CA2686165A1 (OSRAM) |
| WO (2) | WO2008137867A2 (OSRAM) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2290070B1 (en) | 2004-05-28 | 2015-03-25 | Asuragen, Inc. | Methods and compositions involving microRNA |
| ES2534302T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| WO2008137867A2 (en) | 2007-05-03 | 2008-11-13 | Rosetta Inpharmatics Llc | Compositions comprising mir34 therapeutic agents for treating cancer |
| WO2008154333A2 (en) * | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| US8361714B2 (en) | 2007-09-14 | 2013-01-29 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| US8188060B2 (en) * | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| WO2009136501A1 (ja) * | 2008-05-07 | 2009-11-12 | 北海道公立大学法人札幌医科大学 | 癌の検出方法および検出用キット、ならびに癌治療剤 |
| EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| EP2191834A1 (en) * | 2008-11-26 | 2010-06-02 | Centre National De La Recherche Scientifique (Cnrs) | Compositions and methods for treating retrovirus infections |
| LU91545B1 (en) | 2009-03-27 | 2010-09-28 | Univ Luxembourg | Mirna as a prognostic diagnostic biomarker and therapeutic agent for breast cancer and other human associated pathologies |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| FR2948687B1 (fr) | 2009-07-29 | 2015-09-04 | Centre Nat Rech Scient | Utilisation de microarn pour le traitement de pathologies respiratoires chroniques |
| EP2476758A4 (en) * | 2009-09-07 | 2013-04-03 | Yoshiki Murakami | METHOD FOR PREDICTING THE THERAPEUTIC EFFECT ON CHRONIC HEPATITIS C |
| WO2011088309A1 (en) | 2010-01-14 | 2011-07-21 | Regulus Therapeutics Inc. | Microrna compositions and methods |
| WO2011133901A2 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
| WO2011133874A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Multicistronic expression constructs |
| WO2011151321A1 (en) * | 2010-05-31 | 2011-12-08 | Institut Curie | Asf1b as a prognosis marker and therapeutic target in human cancer |
| EP2622076A1 (en) | 2010-09-30 | 2013-08-07 | University of Zürich | Treatment of b-cell lymphoma with microrna |
| CN102031309A (zh) * | 2010-11-30 | 2011-04-27 | 华东师范大学 | miRNA-34c化合物作为脑胶质瘤标志物的应用 |
| EP3178932A1 (en) * | 2011-02-03 | 2017-06-14 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-34 |
| AU2012212105A1 (en) | 2011-02-03 | 2013-09-12 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-124 |
| EP3318635A1 (en) | 2011-04-21 | 2018-05-09 | University of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
| US20130028956A1 (en) | 2011-07-29 | 2013-01-31 | Andre Fischer | Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore |
| US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
| JP2015508282A (ja) * | 2011-12-01 | 2015-03-19 | オハイオ・ステイト・イノベーション・ファウンデーション | 結腸直腸がんにおけるｎｓａｉｄ化学予防に関する材料および方法 |
| WO2013170146A1 (en) | 2012-05-10 | 2013-11-14 | Uab Research Foundation | Methods and compositions for modulating mir-204 activity |
| CN109810977A (zh) | 2012-05-26 | 2019-05-28 | 株式会社博纳克 | 具有递送功能的基因表达调控用单链核酸分子 |
| EP2872147B1 (en) | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
| CA2915443A1 (en) * | 2013-06-16 | 2014-12-24 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| EP3088524A4 (en) * | 2013-12-26 | 2017-08-09 | Tokyo Medical University | Artificial mimic mirna for controlling gene expression, and use of same |
| CA2935022A1 (en) * | 2013-12-27 | 2015-07-02 | Bonac Corporation | Artificial match-type mirna for controlling gene expression and use therefor |
| WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
| EP3209311B1 (en) | 2014-10-21 | 2024-03-06 | University of Massachusetts | Recombinant aav variants and uses thereof |
| AU2015368293B2 (en) | 2014-12-27 | 2021-07-22 | Bonac Corporation | Naturally occuring miRNA for controlling gene expression, and use of same |
| US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
| EP3276003B1 (en) | 2015-03-27 | 2022-07-20 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
| EP3285780A4 (en) | 2015-04-24 | 2018-12-19 | University of Massachusetts | Modified aav constructions and uses thereof |
| EP3364996B1 (en) * | 2015-10-22 | 2021-08-25 | University of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| EP4094780A3 (en) | 2016-02-12 | 2023-02-08 | University of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
| CA3016592A1 (en) * | 2016-03-04 | 2017-09-08 | Rhode Island Hospital | Targeting microrna for cancer treatment |
| EP3216869B1 (en) | 2016-03-09 | 2019-09-18 | Colizzi, Vittorio | Nutraceutical plant derived microrna elements for treatment of leukemia |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| EP4276183A3 (en) | 2017-11-09 | 2023-12-27 | Purmx Therapeutics, Inc. | Pharmaceutical composition comprising mirna-3140 for use in treating cancer |
| CN107699565B (zh) * | 2017-11-24 | 2020-05-22 | 苏州大学 | 微小rna及其在制备抗肿瘤药物中的应用 |
| CN110791566B (zh) * | 2019-10-29 | 2023-06-27 | 徐州市中心医院 | 人shcbp1基因的用途及相关产品 |
| CN111304327B (zh) * | 2020-02-24 | 2024-04-19 | 宋程 | 人grpel2基因的用途及相关产品 |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| CN114010523B (zh) * | 2021-11-05 | 2024-04-12 | 天津穗纳生物医药科技有限公司 | 皮肤抗衰剂及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177568A1 (en) | 1992-12-07 | 2002-11-28 | Stinchcomb Dan T. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US20070032441A1 (en) | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| EP1628993A4 (en) | 2003-05-16 | 2010-04-07 | Rosetta Inpharmatics Llc | METHOD AND COMPOSITIONS FOR RNA INTERFERENCE |
| US6882555B2 (en) | 2003-06-18 | 2005-04-19 | Lattice Semiconductor Corporation | Bi-directional buffering for memory data lines |
| CA2539651A1 (en) | 2003-09-22 | 2005-04-07 | Rosetta Inpharmatics Llc | Synthetic lethal screen using rna interference |
| US7858769B2 (en) | 2004-02-10 | 2010-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA) |
| US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
| CA2566519C (en) | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| EP2290070B1 (en) | 2004-05-28 | 2015-03-25 | Asuragen, Inc. | Methods and compositions involving microRNA |
| WO2007056826A1 (en) * | 2005-11-21 | 2007-05-24 | Johnson & Johnson Research Pty Limited | Multitargeting interfering rnas and methods of their use and design |
| US7893975B2 (en) * | 2006-10-13 | 2011-02-22 | Apple Inc. | System and method for processing images using predetermined tone reproduction curves |
| US8220277B2 (en) * | 2006-11-07 | 2012-07-17 | Tiax Llc | Dehumidification method having multiple different refrigeration paths between the reheat and cooling coils |
| WO2008088858A2 (en) | 2007-01-17 | 2008-07-24 | The Johns Hopkins University | Compositions and methods featuring micronas for treating neoplasia |
| ATE553196T1 (de) | 2007-02-27 | 2012-04-15 | Rosetta Genomics Ltd | Zusammensetzung und verfahren zur modulation von zellproliferation und zelltod |
| WO2008137867A2 (en) | 2007-05-03 | 2008-11-13 | Rosetta Inpharmatics Llc | Compositions comprising mir34 therapeutic agents for treating cancer |
-
2008
- 2008-05-05 WO PCT/US2008/062689 patent/WO2008137867A2/en not_active Ceased
- 2008-05-05 WO PCT/US2008/062681 patent/WO2008137862A2/en not_active Ceased
- 2008-05-05 JP JP2010506716A patent/JP2010525826A/ja active Pending
- 2008-05-05 US US12/598,563 patent/US8399248B2/en active Active
- 2008-05-05 US US12/598,590 patent/US8378088B2/en active Active
- 2008-05-05 CA CA 2686165 patent/CA2686165A1/en not_active Abandoned
- 2008-05-05 EP EP08747666.9A patent/EP2152722B1/en active Active
- 2008-05-05 AU AU2008247427A patent/AU2008247427A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525826A5 (OSRAM) | ||
| Cheunsuchon et al. | Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas | |
| JP2010530239A5 (OSRAM) | ||
| Sun et al. | SNPs in human miRNA genes affect biogenesis and function | |
| CN102892897B (zh) | 用于肺癌的微rna表达谱分析的组合物和方法 | |
| JP2007512027A5 (OSRAM) | ||
| EP2112235A1 (en) | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma | |
| JP2009516512A5 (OSRAM) | ||
| US20120053224A1 (en) | Compositions and methods for micro-rna expression profiling of cancer stem cells | |
| JP2015518714A5 (OSRAM) | ||
| JP2012503493A5 (OSRAM) | ||
| CN103080334B (zh) | 用于诊断早期结直肠癌及高级腺瘤的微rna生物标记及方法 | |
| JP2017535552A5 (OSRAM) | ||
| JP2018512155A5 (OSRAM) | ||
| JP2010525813A5 (OSRAM) | ||
| JP2015502365A5 (OSRAM) | ||
| JP2010539940A5 (OSRAM) | ||
| WO2019196887A1 (zh) | 一种新型小激活rna | |
| JP2014527807A5 (OSRAM) | ||
| JP6970732B2 (ja) | Ｒｎａ検出用キット及び方法 | |
| CN104673883B (zh) | 用于预测早期非转移性结直肠癌预后的微rna生物标记物及检测方法 | |
| CN102876796A (zh) | 鉴别产绿壳蛋鸡及鸡绿壳蛋基因型的方法及专用片段与引物 | |
| JP2004520833A5 (OSRAM) | ||
| EP2570492A3 (en) | Method for detecting mutations at genes IL28B (RS8099917) and ITPA (RS1127354) | |
| Nana-Sinkam et al. | MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application |